Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin A Randomized Clinical Trial

被引:233
|
作者
Martens, Thomas [1 ]
Beck, Roy W. [2 ]
Bailey, Ryan [2 ]
Ruedy, Katrina J. [2 ]
Calhoun, Peter [2 ]
Peters, Anne L. [3 ]
Pop-Busui, Rodica [4 ]
Philis-Tsimikas, Athena [5 ]
Bao, Shichun [6 ]
Umpierrez, Guillermo [7 ]
Davis, Georgia [7 ]
Kruger, Davida [8 ]
Bhargava, Anuj [9 ]
Young, Laura [10 ]
McGill, Janet B. [11 ]
Aleppo, Grazia [12 ]
Nguyen, Quang T. [13 ]
Orozco, Ian [14 ]
Biggs, William [15 ]
Lucas, K. Jean [16 ]
Polonsky, William H. [17 ]
Buse, John B. [10 ]
Price, David [18 ]
Bergenstal, Richard M. [19 ]
Group, Mobile Study
机构
[1] Pk Nicollet Internal Med, Int Diabet Ctr, Minneapolis, MN USA
[2] Jaeb Ctr Hlth Res, Tampa, FL USA
[3] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA
[4] Univ Michigan, Ann Arbor, MI 48109 USA
[5] Scripps Whittier Diabet Inst, San Diego, CA USA
[6] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[7] Emory Univ, Sch Med, Atlanta, GA USA
[8] Henry Ford Hlth Syst, Detroit, MI USA
[9] Iowa Diabet Res, W Des Moines, IA USA
[10] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA
[11] Washington Univ, Sch Med, St Louis, MO USA
[12] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[13] Las Vegas Endocrinol, Henderson, NV USA
[14] Carteret Med Grp, Morehead City, NC USA
[15] Amarillo Med Specialists, Amarillo, TX USA
[16] Diabet & Endocrinol Consultants Pc, Morehead City, NC USA
[17] Behav Diabet Inst, San Diego, CA USA
[18] Dexcom Inc, San Diego, CA USA
[19] HealthPartners Inst, Int Diabet Ctr, Minneapolis, MN USA
来源
关键词
HYPOGLYCEMIA; INJECTIONS;
D O I
10.1001/jama.2021.7444
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Continuous glucose monitoring (CGM) has been shown to be beneficial for adults with type 2 diabetes using intensive insulin therapy, but its use in type 2 diabetes treated with basal insulin without prandial insulin has not been well studied. OBJECTIVE To determine the effectiveness of CGM in adults with type 2 diabetes treated with basal insulin without prandial insulin in primary care practices. DESIGN, SETTING, AND PARTICIPANTS This randomized clinical trialwas conducted at 15 centers in the US (enrollment from July 30, 2018, to October 30, 2019; follow-up completed July 7, 2020) and included adults with type 2 diabetes receiving their diabetes care from a primary care clinician and treated with 1 or 2 daily injections of long- or intermediate-acting basal insulin without prandial insulin, with or without noninsulin glucose-lowering medications. INTERVENTIONS Random assignment 2:1 to CGM (n = 116) or traditional blood glucose meter (BGM) monitoring (n = 59). MAIN OUTCOMES AND MEASURES The primary outcome was hemoglobin A1c (HbA1c) level at 8 months. Key secondary outcomes were CGM-measured time in target glucose range of 70 to 180mg/dL, time with glucose level at greater than 250mg/dL, and mean glucose level at 8 months. RESULTS Among 175 randomized participants (mean [SD] age, 57 [9] years; 88 women [50%]; 92 racial/ethnic minority individuals [53%]; mean [SD] baseline HbA1c level, 9.1% [0.9%]), 165 (94%) completed the trial. Mean HbA1c level decreased from 9.1% at baseline to 8.0% at 8 months in the CGM group and from 9.0% to 8.4% in the BGM group (adjusted difference, -0.4%[95% CI, -0.8% to -0.1%]; P =.02). In the CGM group, compared with the BGM group, the mean percentage of CGM-measured time in the target glucose range of 70 to 180mg/dL was 59% vs 43%(adjusted difference, 15%[95% CI, 8% to 23%]; P <.001), the mean percentage of time at greater than 250mg/dL was 11% vs 27%(adjusted difference, -16%[95% CI, -21% to -11%]; P <.001), and the means of the mean glucose values were 179mg/dL vs 206mg/dL (adjusted difference, -26mg/dL [95% CI, -41 to -12]; P <.001). Severe hypoglycemic events occurred in 1 participant (1%) in the CGM group and in 1 (2%) in the BGM group. CONCLUSIONS AND RELEVANCE Among adults with poorly controlled type 2 diabetes treated with basal insulin without prandial insulin, continuous glucose monitoring, as compared with blood glucose meter monitoring, resulted in significantly lower HbA1c levels at 8 months.
引用
收藏
页码:2262 / 2272
页数:11
相关论文
共 50 条
  • [1] Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin Reply
    Martens, Thomas W.
    Beck, Roy W.
    Bergenstal, Richard M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (13): : 1330 - +
  • [2] Continuous Glucose Monitoring Improves Glycemic Control in Subjects With Type 2 Diabetes on Basal Insulin
    Manning, James P.
    Halford, Jean R.
    Liljenquist, David R.
    Sulik, Mark B.
    Sulik, Rebecca T.
    [J]. DIABETES, 2012, 61 : A587 - A587
  • [3] Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections The DIAMOND Randomized Clinical Trial
    Beck, Roy W.
    Riddlesworth, Tonya
    Ruedy, Katrina
    Ahmann, Andrew
    Bergenstal, Richard
    Haller, Stacie
    Kollman, Craig
    Kruger, Davida
    McGill, Janet B.
    Polonsky, William
    Toschi, Elena
    Wolpert, Howard
    Price, David
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (04): : 371 - 378
  • [4] Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes A Randomized Clinical Trial
    Laffel, Lori M.
    Kanapka, Lauren G.
    Beck, Roy W.
    Bergamo, Katherine
    Clements, Mark A.
    Criego, Amy
    DeSalvo, Daniel J.
    Goland, Robin
    Hood, Korey
    Liljenquist, David
    Messer, Laurel H.
    Monzavi, Roshanak
    Mouse, Thomas J.
    Prahalad, Priya
    Sherr, Jennifer
    Simmons, Jill H.
    Wadwa, R. Paul
    Weinstock, Ruth S.
    Willi, Steven M.
    Miller, Kellee M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (23): : 2388 - 2396
  • [5] The Durability of Basal Insulin Affects Day-to-Day Glycemic Variability Assessed by Continuous Glucose Monitoring in Type 2 Diabetes Patients: A Randomized Crossover Trial
    Iuchi, Hiroyuki
    Sakamoto, Masaya
    Matsutani, Daisuke
    Suzuki, Hirofumi
    Horiuchi, Ryuzo
    Utsunomiya, Kazunori
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2017, 19 (08) : 457 - 462
  • [6] Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections The GOLD Randomized Clinical Trial
    Lind, Marcus
    Polonsky, William
    Hirsch, Irl B.
    Heise, Tim
    Bolinder, Jan
    Dahlqvist, Sofia
    Schwarz, Erik
    Olafsdottir, Arndis Finna
    Frid, Anders
    Wedel, Hans
    Ahlen, Elsa
    Nystrom, Thomas
    Hellman, Jarl
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (04): : 379 - 387
  • [7] Effectiveness of Continuous Glucose Monitoring in Older Adults with Type 2 Diabetes Treated with Basal Insulin
    Bao, Shichun
    Bailey, Ryan
    Calhoun, Peter
    Beck, Roy W.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 (05) : 299 - 306
  • [8] Assessing glycemic excursions by continuous glucose monitoring system (CGMS) in patients with type 2 diabetes treated with insulin secretagogues
    Li, Yan
    Xu, Lijuan
    Shen, Jie
    Ran, Jianmin
    Zhang, Yang
    Wang, Min
    Yan, Li
    Fu, Zuzhi
    [J]. DIABETES, 2008, 57 : A546 - A546
  • [9] Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Mellitus and CKD
    Presswala, Lubaina
    Hong, Susana
    Harris, Yael
    Romao, Isabela
    Zhang, Meng
    Jhaveri, Kenar D.
    Sakhiya, Vipul
    Fishbane, Steven
    [J]. KIDNEY MEDICINE, 2019, 1 (05) : 281 - 287
  • [10] Interest of Continuous Glucose Monitoring to Improve Glycemic Control in Patients With Type 2 Diabetes and End-Stage Renal Disease Treated by Basal-Bolus Insulin Regimen
    Kepenekian, Lori
    Smagala, Agnieszka
    Meyer, Laurent
    Imhoff, Olivier
    Sissoko, Aicha
    Serb, Liviu
    Krummel, Thierry
    Dorey, Francois
    Fleury, Dominique
    Le Floch, Jean-Pierre
    Chantrel, Francois
    Kessler, Laurence
    [J]. DIABETES, 2013, 62 : A227 - A227